Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803692 | 1.00 | HSD11B1 (0.40) | HSD11B1ASGR1JAK2JAK1JAK3 | |
| SCHEMBL190837 | 0.88 | HSD11B1 (0.47) | HSD11B1ASGR1JAK2JAK1JAK3 | |
| SCHEMBL24622292 | 0.85 | HSD11B1 (0.41) | HSD11B1ASGR1KDM4D | |
| Formic Acid SCHEMBL27813341 | 0.83 | HSD11B1 (0.42) | HSD11B1ASGR1JAK2JAK1JAK3 | |
| SCHEMBL4797728 | 0.83 | HSD11B1 (0.38) | HSD11B1ASGR1KDM4D | |
| SCHEMBL4797721 | 0.83 | HSD11B1 (0.38) | HSD11B1ASGR1KDM4D | |
| SCHEMBL4938252 | 0.83 | HSD11B1 (0.41) | HSD11B1ASGR1KDM4DKAT8 | |
| SCHEMBL28804053 | 0.82 | HSD11B1 (0.44) | HSD11B1ASGR1JAK2JAK1JAK3 | |
| SCHEMBL28804055 | 0.82 | HSD11B1 (0.44) | HSD11B1ASGR1JAK2JAK1JAK3 | |
| SCHEMBL228179 | 0.82 | HSD11B1 (0.46) | HSD11B1ASGR1KDM4DPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954219-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20180282313-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-3121175-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-25 | — | — | EP | disclosed |
| WO-2008093946-A1 | POLARIZING PLATE HAVING PRESSURE-SENSITIVE ADHESIVE LAYER WITH IMPROVED LIGHT LEAKAGE PROPERTY | LG CHEM, LTD. (KR) | 2008-08-07 | — | — | WO | disclosed |
| EP-1311475-B1 | AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008088115-A1 | ACRYLIC PRESSURE SENSITIVE ADHESIVE COMPOSITIONS | LG CHEM, LTD. (KR) | 2008-07-24 | — | — | WO | disclosed |
| US-7335687-B2 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1458683-B1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7012077-B2 | Substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | ACKERMANN JEAN (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1458683-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-20030186984-A1 | Substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003053933-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| EP-1311475-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2002014267-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282313-A1 | 1,3-BENZODIOXOLE DERIVATIVE | EZH1, EZH2, BMI1 | HSD11B1 294/4885ASGR1 4175/4885JAK2 62/4885 |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | EZH1, EZH2, BMI1 | HSD11B1 294/4885ASGR1 4175/4885JAK2 62/4885 |
| US-20030186984-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | HSD11B1 19/4885ASGR1 1121/4885JAK2 3542/4885 |
| US-10017500-B2 | 1,3-benzodioxole derivative | EZH1, EZH2, BMI1 | HSD11B1 294/4885ASGR1 4175/4885JAK2 62/4885 |
| US-10954219-B2 | 1,3-benzodioxole derivative | EZH1, EZH2, BMI1 | HSD11B1 294/4885ASGR1 4175/4885JAK2 62/4885 |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | HSD11B1 14/4885ASGR1 1643/4885JAK2 3858/4885 |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | HSD11B1 14/4885ASGR1 1643/4885JAK2 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.